BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
Source: View publication →
The first-in-class EGFR-HER3 bispecific antibody-drug conjugate BL-B01D1 demonstrated promising preliminary antitumor activity and a manageable, predominantly hematologic safety profile in heavily pretreated patients with advanced solid tumors.
Key Findings
Study Design
Study Limitations
Clinical Significance
This landmark first-in-human trial establishes the clinical viability of dual EGFR-HER3 targeting via a bispecific antibody-drug conjugate (ADC). By simultaneously engaging two strongly co-expressed receptors often implicated in resistance to standard targeted therapies, BL-B01D1 offers a novel mechanism to deliver cytotoxic payloads to tumor cells. The robust objective response rate of 34% in heavily pretreated patients—particularly those with NSCLC and nasopharyngeal carcinoma—supports its further development. Notably, while the drug is highly active, its toxicity profile is heavily weighted toward myelosuppression rather than the interstitial lung disease frequently seen with other topoisomerase-I ADCs, dictating the need for careful hematologic monitoring in clinical practice.
Historical Context
Antibody-drug conjugates (ADCs) have revolutionized targeted oncology by utilizing monoclonal antibodies to selectively deliver potent cytotoxic payloads directly to tumor cells. While agents targeting single antigens like HER2 (e.g., trastuzumab deruxtecan) or Trop-2 (e.g., sacituzumab govitecan) have become standard of care, acquired resistance frequently limits long-term efficacy. EGFR and HER3 are ErbB family members often co-expressed in solid tumors, where HER3 acts as a key bypass signaling node promoting resistance to EGFR-directed therapies. BL-B01D1 (izalontamab brengitecan) was engineered as a first-in-class bispecific ADC to overcome this by requiring dual antigen binding, theoretically enhancing tumor specificity and cellular internalization. This trial marks the first clinical validation of this bispecific ADC approach, leading to its rapid advancement into phase 2 and 3 trials and earning it FDA Breakthrough Therapy Designation.
Guided Discussion
High-yield insights from every perspective
How does a bispecific antibody-drug conjugate (ADC) targeting both EGFR and HER3 theoretically overcome resistance mechanisms typically seen with traditional single-target EGFR tyrosine kinase inhibitors?
Key Response
This tests foundational knowledge of receptor tyrosine kinase crosstalk. HER3 lacks an active kinase domain but forms potent heterodimers with EGFR, serving as a major bypass resistance mechanism via PI3K/AKT signaling when EGFR alone is inhibited. Targeting both simultaneously prevents this escape route, while the ADC payload delivers direct cytotoxicity.
The phase 1 study of BL-B01D1 noted a 'predominantly hematologic safety profile.' Given that naked EGFR antibodies typically cause profound dermatologic and gastrointestinal toxicities, why does this ADC present primarily with bone marrow suppression?
Key Response
This highlights the clinical distinction between on-target, off-tumor effects (such as rash or diarrhea from EGFR inhibition in skin and gut) and the effects of the cytotoxic payload linked to the ADC. The payload often causes systemic hematologic toxicity when prematurely released into circulation or via the bystander effect affecting rapidly dividing hematopoietic cells.
In early-phase trials evaluating bispecific ADCs across heterogeneous solid tumors, how should we approach patient selection regarding EGFR and HER3 target expression, considering the variable bystander effect of the payload?
Key Response
Fellows must grapple with nuanced biomarker selection. Unlike naked antibodies, ADCs with membrane-permeable payloads can kill adjacent target-negative tumor cells (the bystander effect). Therefore, high dual target expression may not be strictly required for efficacy, complicating the establishment of predictive immunohistochemistry cutoffs for patient selection.
As BL-B01D1 and similar ADCs advance to later-stage trials, how will their prominent hematologic toxicity profiles complicate sequencing them with existing myelosuppressive standards of care in heavily pretreated patients?
Key Response
Attendings must consider real-world treatment sequencing and cumulative toxicities. Managing profound neutropenia or thrombocytopenia in patients who have already exhausted platinum doublets or prior ADCs requires strategic dose reductions, growth factor support, and careful patient selection to maintain quality of life while maximizing efficacy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In a first-in-human trial of a bispecific ADC, how does the complexity of target-mediated drug disposition (TMDD) for two distinct receptors influence the selection of the optimal dose-escalation statistical design?
Key Response
Bispecific ADCs exhibit complex, non-linear pharmacokinetics due to binding two variably expressed targets. Traditional 3+3 or simple BOIN models may fail to capture these intricate PK/PD relationships, requiring more advanced model-based designs (like continual reassessment methods incorporating PK covariates) to safely identify the recommended phase 2 dose.
For an open-label, dose-escalation study evaluating an ADC across multiple solid tumor types, what are the primary methodological concerns regarding pooling safety and efficacy data to determine a single recommended Phase 2 dose (RP2D)?
Key Response
A rigorous reviewer would flag that an RP2D derived from a pooled, biologically heterogeneous population might not be optimal for all tumor types. Differences in baseline bone marrow reserve, prior therapy lines, and target expression across lung, breast, or gastrointestinal cohorts threaten the validity of a one-size-fits-all dosing strategy.
Based on promising phase 1 data, what specific efficacy and safety endpoints are mandatory in subsequent phase 2/3 trials before integrating novel bispecific ADCs like BL-B01D1 into NCCN or ESMO clinical practice guidelines for refractory solid tumors?
Key Response
Guideline committees require robust evidence before altering standards of care. While phase 1 objective response rates are promising, committees look for randomized phase 3 data demonstrating statistically significant improvements in overall survival (OS) or progression-free survival (PFS) compared to standard-of-care chemotherapy, along with manageable toxicity, before assigning a Category 1 or 2A recommendation.
Clinical Landscape
Noteworthy Related Trials
CHRYSALIS Trial
Tested
Amivantamab (EGFR-MET bispecific antibody)
Population
Advanced NSCLC harboring EGFR exon 20 insertion mutations post-chemotherapy
Comparator
None (Single-arm)
Endpoint
Overall Response Rate (ORR)
HERTHENA-Lung01 Trial
Tested
Patritumab deruxtecan (HER3-directed ADC)
Population
EGFR-mutated advanced NSCLC previously treated with EGFR TKI and chemotherapy
Comparator
None (Single-arm)
Endpoint
Objective Response Rate (ORR)
DESTINY-PanTumor02 Trial
Tested
Trastuzumab deruxtecan (HER2-directed ADC)
Population
Patients with previously treated HER2-expressing advanced solid tumors
Comparator
None (Single-arm)
Endpoint
Objective Response Rate (ORR)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis